Ocular Surface Disease in Glaucoma Patients on Long-Term Therapy

NCT07841912 | Not Yet Recruiting

• 1 other identifier: OSD-Glaucoma-Assiut-2026
• Study Type: observational
• Target: 55
• Locations: 0 countries
• Sites: N/A

Brief Summary

This cross-sectional study aims to determine the prevalence and severity of ocular surface disease among adult patients with glaucoma receiving long-term topical antiglaucoma medications.

Conditions

Glaucoma; Ocular Surface Disease; Dry Eye

Keywords

Ocular surface disease; Glaucoma; OSDI; Topical antiglaucoma medications; Assiut

Outcome Measures

Primary Outcomes (1)

• Prevalence of ocular surface disease

  Proportion of patients with ocular surface disease defined as an Ocular Surface Disease Index (OSDI) score ≥13.

  Baseline

Secondary Outcomes (7)

• Proportion of Patients with Mild Ocular Surface Disease Symptoms

  Baseline

• Proportion of Patients with Moderate Ocular Surface Disease Symptoms

  Baseline

• Proportion of Patients with Severe Ocular Surface Disease Symptoms

  Baseline

• Mean OSDI score

  Baseline

• Tear film break-up time (TBUT)

  Baseline

Study Arms (1)

Single cohort: Glaucoma patients on long-term topical therapy

Adult patients with glaucoma receiving topical antiglaucoma medications for at least 6 months who will undergo OSDI questionnaire and clinical ocular surface assessment.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with diagnosed glaucoma receiving long-term topical antiglaucoma medications at Assiut University Hospital and El Mabarra Hospital.

You may qualify if:

• \- Age 18 years or older
• Diagnosed glaucoma
• Currently receiving one or more topical antiglaucoma medications
• Duration of topical antiglaucoma treatment ≥6 months
• Written informed consent

You may not qualify if:

• \- Current use of concomitant topical ocular medication that may affect the ocular surface (e.g., topical cyclosporine)
• Previous ocular surgery within the preceding 6 months
• History of corneal surgery or significant ocular trauma affecting the ocular surface
• Active ocular infection or significant active ocular inflammation
• Contact lens wear
• Systemic autoimmune or connective tissue diseases known to affect the ocular surface (e.g., Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus)
• Significant corneal pathology interfering with ocular surface assessment

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Glaucoma; Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Ocular Hypertension; Eye Diseases; Lacrimal Apparatus Diseases

Study Officials

• Mohamed s Abdel-rehim, prof

  Ophthalmology Department, Assiut University Hospitals

  STUDY CHAIR

Central Study Contacts

Margo f Awad, Resident

CONTACT

+20 12 73302611; margo19.mahros@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 20, 2026
• First Posted: September 25, 2026
• Study Start: September 26, 2026
• Primary Completion (Estimated): September 26, 2027
• Study Completion (Estimated): April 20, 2028
• Last Updated: September 28, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share